Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Genetic variations in 3'UTRs of SMUG1 and NEIL2 genes modulate breast cancer risk, survival and therapy response

A. Cumova, V. Vymetalkova, A. Opattova, V. Bouskova, B. Pardini, K. Kopeckova, R. Kozevnikovova, K. Lickova, M. Ambrus, L. Vodickova, A. Naccarati, P. Soucek, P. Vodicka

. 2021 ; 36 (4) : 269-279. [pub] 20210827

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Breast cancer (BC) is the most frequent malignancy in women accounting for approximately 2 million new cases worldwide annually. Several genetic, epigenetic and environmental factors are known to be involved in BC development and progression, including alterations in post-transcriptional gene regulation mediated by microRNAs (miRNAs). Single nucleotide polymorphisms (SNPs) located in miRNA binding sites (miRSNPs) in 3'-untranslated regions of target genes may affect miRNA-binding affinity and consequently modulate gene expression. We have previously reported a significant association of miRSNPs in the SMUG1 and NEIL2 genes with overall survival in colorectal cancer patients. SMUG1 and NEIL2 are DNA glycosylases involved in base excision DNA repair. Assuming that certain genetic traits are common for solid tumours, we have investigated wherever variations in SMUG1 and NEIL2 genes display an association with BC risk, prognosis, and therapy response in a group of 673 BC patients and 675 healthy female controls. Patients with TC genotype of NEIL2 rs6997097 and receiving only hormonal therapy displayed markedly shorter overall survival (HR = 4.15, 95% CI = 1.7-10.16, P = 0.002) and disease-free survival (HR = 2.56, 95% CI = 1.5-5.7, P = 0.02). Our results suggest that regulation of base excision repair glycosylases operated by miRNAs may modulate the prognosis of hormonally treated BC.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012284
003      
CZ-PrNML
005      
20220506130120.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/mutage/geab017 $2 doi
035    __
$a (PubMed)34097065
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Cumova, Andrea $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, 14200, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, 12800, Czech Republic
245    10
$a Genetic variations in 3'UTRs of SMUG1 and NEIL2 genes modulate breast cancer risk, survival and therapy response / $c A. Cumova, V. Vymetalkova, A. Opattova, V. Bouskova, B. Pardini, K. Kopeckova, R. Kozevnikovova, K. Lickova, M. Ambrus, L. Vodickova, A. Naccarati, P. Soucek, P. Vodicka
520    9_
$a Breast cancer (BC) is the most frequent malignancy in women accounting for approximately 2 million new cases worldwide annually. Several genetic, epigenetic and environmental factors are known to be involved in BC development and progression, including alterations in post-transcriptional gene regulation mediated by microRNAs (miRNAs). Single nucleotide polymorphisms (SNPs) located in miRNA binding sites (miRSNPs) in 3'-untranslated regions of target genes may affect miRNA-binding affinity and consequently modulate gene expression. We have previously reported a significant association of miRSNPs in the SMUG1 and NEIL2 genes with overall survival in colorectal cancer patients. SMUG1 and NEIL2 are DNA glycosylases involved in base excision DNA repair. Assuming that certain genetic traits are common for solid tumours, we have investigated wherever variations in SMUG1 and NEIL2 genes display an association with BC risk, prognosis, and therapy response in a group of 673 BC patients and 675 healthy female controls. Patients with TC genotype of NEIL2 rs6997097 and receiving only hormonal therapy displayed markedly shorter overall survival (HR = 4.15, 95% CI = 1.7-10.16, P = 0.002) and disease-free survival (HR = 2.56, 95% CI = 1.5-5.7, P = 0.02). Our results suggest that regulation of base excision repair glycosylases operated by miRNAs may modulate the prognosis of hormonally treated BC.
650    12
$a 3' nepřekládaná oblast $7 D020413
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádory prsu $x enzymologie $x epidemiologie $x genetika $x terapie $7 D001943
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a DNA-glykosylasy $x genetika $7 D045647
650    _2
$a oprava DNA $7 D004260
650    _2
$a DNA-lyasa (apurinová nebo apyrimidinová) $x genetika $7 D043603
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mikro RNA $x metabolismus $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    12
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a prognóza $7 D011379
650    _2
$a riziko $7 D012306
650    _2
$a uracil-DNA-glykosidasa $x genetika $7 D051981
650    _2
$a běloši $x genetika $7 D044465
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vymetalkova, Veronika $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, 14200, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, 12800, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, 306 05, Czech Republic $1 https://orcid.org/0000000168706788 $7 xx0102721
700    1_
$a Opattova, Alena $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, 14200, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, 12800, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, 306 05, Czech Republic
700    1_
$a Bouskova, Veronika $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, 306 05, Czech Republic
700    1_
$a Pardini, Barbara $u IIGM Italian Institute for Genomic Medicine, Candiolo, 10060, Italy $u Candiolo Cancer Institute, FPO-IRCCS, Candiolo, 10060, Italy $1 https://orcid.org/0000000195714257
700    1_
$a Kopeckova, Katerina $u Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, 15006, Czech Republic
700    1_
$a Kozevnikovova, Renata $u Onkocentrum, MEDICON Services s.r.o., Prague, 14000, Czech Republic
700    1_
$a Lickova, Katerina $u Radiotherapy and Oncology Department, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, 10034, Czech Republic
700    1_
$a Ambrus, Miloslav $u Radiotherapy and Oncology Department, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, 10034, Czech Republic
700    1_
$a Vodickova, Ludmila $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, 14200, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, 12800, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, 306 05, Czech Republic
700    1_
$a Naccarati, Alessio $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, 14200, Czech Republic $u IIGM Italian Institute for Genomic Medicine, Candiolo, 10060, Italy $u Candiolo Cancer Institute, FPO-IRCCS, Candiolo, 10060, Italy
700    1_
$a Soucek, Pavel $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, 306 05, Czech Republic $u Toxicogenomics Unit, National Institute of Public Health, Prague, 10000, Czech Republic
700    1_
$a Vodicka, Pavel $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, 14200, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, 12800, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, 306 05, Czech Republic
773    0_
$w MED00003429 $t Mutagenesis $x 1464-3804 $g Roč. 36, č. 4 (2021), s. 269-279
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34097065 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130113 $b ABA008
999    __
$a ok $b bmc $g 1789741 $s 1163485
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 36 $c 4 $d 269-279 $e 20210827 $i 1464-3804 $m Mutagenesis $n Mutagenesis $x MED00003429
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...